Endocrinology

December 6th 2023

An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.

December 4th 2023

Announced on December 04, 2023, the approved label changes allow for administration regardless of timing of proton pump administration and for administration 15 minutes before breakfast.

December 4th 2023

In a new study focusing on adults with type 1 diabetes and mild-moderate depressive symptomatology, a CBT program helped depression symptoms, quality of life, anxiety, treatment adherence, and total diabetes-related stress in emotional, physical, and impersonal subscales.

December 4th 2023

Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.